ICU vs ENTX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 24, 2026

ICU

45.2
AI Score
VS
ICU Wins

ENTX

42.5
AI Score

Investment Advisor Scores

ICU

45score
Recommendation
HOLD

ENTX

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ICU ENTX Winner
Net Income -7.25M -10.82M ICU
Operating Income -7.39M -8.10M ICU
ROE -168.8% -148.9% ENTX
ROA -83.8% -55.5% ENTX
Total Assets 8.65M 19.48M ENTX
Cash 6.96M 11.31M ENTX
Current Ratio 1.89 8.98 ENTX

Relative Price Performance (Last 90 Days)

ICU 1M: -29.9% · 3M: -32.5% ENTX 1M: +4.3% · 3M: -25.5%

Current Technical Phase

ICU

Markdown
Sell / avoid

Price below a falling SMA50 (slope -0.8%), weak momentum, RSI 37

RSI (14): 36.8 · Price: $2.41

ENTX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 55

RSI (14): 54.9 · Price: $2.92

Fundamentals Snapshot

Metric ICU ENTX
Market Cap — —
Forward P/E -1.0 -7.0
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.8% -1.0%
Gross Margin 0.9% —
Operating Margin -6.2% 0.0%
EPS -2.97 -0.36
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ICU is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.